Navigation Links
Flexible, steerable endoscope with working channel

ProductsFlexible, steerable endoscope with working channel
Company B. Braun Medical Inc.
Item Flexible, steerable endoscope with working channel
Features Deflection up and down. Working channel for use of different micro instruments and electrodes (diam. 1.4 mm).
Description The flexible endoscope was mainly developed for the pure neuroendoscopy. Due to the working channel it is ideal suitable for therapeutic indications e.g. subdural hematomas, cysts or intraventricular indications.
Info B. Braun Medical Inc.
Customer Service: (610) 691-5400

Related medicine products :

1. Neuroview Rigid Body Fiberoptic Neuroendoscopes
2. Neuroview 1.2 mm Neuroendoscopes
3. Neuroview Flexible Neuroendoscopes
4. Pediatric Neuroendoscope System
5. CODMAN Steerable Neuroendoscope
6. XL Advantage 3.5x @ 34cm working distance
7. XL Advantage 3.5x @ 46cm working distance
8. XL Advantage 4.5x @ 34cm working distance
9. XL Advantage 4.5x @ 42cm working distance
10. XL Advantage 4.5x @ 46cm working distance
11. XL Advantage 5.5x @ 34cm working distance
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc, ...
... take their eyes for granted. Like ... eyes need proper nutrition and care ... vision as you age. In fact, ... to maintaining and preserving eye health ...
... The herbal extracts, vitamins, minerals, ... increases circulation to ocular tissue, ... healthy function of the lens ... This formula is optimized to ...
Online Unity Interlaboratory QC Data Management...
Medicine Products:
(Date:6/18/2013)... The world,s first computer guided fitness training system ... of the three winners of the LeWeb,13 London ... , The startup company, Genetrainer, building on ... PhD graduate, Ralph Pethica and Julian Gough, Professor ... Science, was selected from over 350 startups to ...
(Date:6/18/2013)... June 18, 2013 On June 12th, ... everything about medical marijuana in Canada . ... republish the new Canadian Marijuana for Medical Purposes Regulation ... department of Health Canada. , The Canabud.ca website is ... rapidly growing industry. “As medical marijuana becomes more ...
(Date:6/18/2013)... GA (PRWEB) June 18, 2013 Dr. ... of the Atlanta Vision Institute, is pleased to announce ... next generation of Intralase LASIK equipment, the iFS™ Advanced ... only LASIK practice in Atlanta to offer its patients ... Ashraf is giving his patients a complimentary upgrade to ...
(Date:6/18/2013)... 2013 The Skin and Vein Center ... public on July 9 from 2 p.m. to 5 p.m. ... with the doctor or a nurse, who will give the ... or nurse will inform the patient of the health of ... available for varicose and spider veins. , As part of ...
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 Visitors to New ... a spa promotion from the famed JW Marriott Essex House ... New York City for business or pleasure, guests can take a ... rejuvenating day surrounded by serenity at The Spa at Essex House. ... at the Central Park hotel starting at $379 per night plus ...
Breaking Medicine News(10 mins):Health News:Atlanta LASIK Surgeon Offers New LASIK Technology 2Health News:Kansas City Dermatologists at The Skin and Vein Center Offer Complimentary Vein Screening on July 9 2Health News:New Spa Deal From JW Marriott Essex House New York Will Delight, Relax Visitors 2Health News:New Spa Deal From JW Marriott Essex House New York Will Delight, Relax Visitors 3
... Johns Hopkins University School of Medicine have identified a ... novel autoantibody specificity that makes them potential candidates for ... September issue of Arthritis & Rheumatism , a ... Myopathy is a term used to describe muscle disease. ...
... Aug. 19 (HealthDay News)-- There were no smiles on the faces ... waiting on line for help from the Oregon Employment Department were ... lecture from a middle-aged woman, who leaned in close and whispered ... a lot of unhappy, stressed people here." At rows of ...
... the mainstream media has led many researchers to study ... have indicated that there is a link between exposure ... of sexual activity among teens. However, a study led ... Published this month in the online version of ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Aug. ... eggs has sickened more than 250 people and led to ... news reports. The outbreak, which apparently began in May, ... and Prevention said. On Aug. 13, the CDC said: ...
... School of Medicine in Baltimore have developed a novel ... treatment for ventricular tachycardia, a potentially life-threatening heart rhythm ... The new approach couples CT (computed tomography) images with ... the heart that produce arrhythmias. The results of a ...
... Center in Israel have determined that the use ... outcome for patients undergoing percutaneous coronary intervention (PCI), ... appear in the September issue of Catheterization ... Wiley-Blackwell on behalf of The Society for Cardiovascular ...
Cached Medicine News:Health News:Novel autoantibodies identified in patients with necrotizing myopathy 2Health News:Novel autoantibodies identified in patients with necrotizing myopathy 3Health News:Jobless and Stressed but Holding Out Hope 2Health News:For teens, early sex and media exposure not linked 2Health News:Nationwide Egg Recall Underway 2Health News:Innovative imaging system may boost speed and accuracy in treatment of heart rhythm disorder 2Health News:Innovative imaging system may boost speed and accuracy in treatment of heart rhythm disorder 3Health News:Innovative imaging system may boost speed and accuracy in treatment of heart rhythm disorder 4Health News:Drug-eluting stents confirmed safe, effective for long-term use 2
(Date:6/18/2013)... June 18, 2013 The board of directors ... ) has declared a dividend for the third quarter ... stock. The dividend is payable September ... of business on August 15, 2013. Lilly, ... of pharmaceutical products by applying the latest research from ...
(Date:6/18/2013)... Today, Wall Street Reports announced new research reports ... Management Associates Inc. (NYSE: HMA ), IDEXX Laboratories, ... ISIS ), and Trius Therapeutics Inc. (NASDAQ: TSRX). ... including full price targets, industry analysis and analyst ratings - ... Report On June 7, 2013, Gilead Sciences Inc. ...
(Date:6/18/2013)... And EMERYVILLE, Calif. , ... presented final results today from a Phase 2/3 ... capsules demonstrating a statistically significant improvement in levodopa-induced ... at week 8 versus placebo in the Unified ... extended-release formulation of amantadine intended for once-nightly administration ...
Breaking Medicine Technology:Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6